PYXS — Pyxis Oncology, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-10-08.
Performance
Technicals
Others in Healthcare
Measured signals that fired on PYXS
| date | signal | measured base rate |
|---|---|---|
| 2026-06-11 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-03-05 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-30 | Dupont Jakob Director | Open-market sale 10b5-1 plan | 35.0K | 3.06 | 107.1K |
| 2026-06-30 | Dupont Jakob Director | Option exercise 10b5-1 plan | 35.0K | 1.60 | 56.0K |
| 2026-03-24 | Wadhane Jitendra Prin Fin & Acct Officer | Grant or award | 109.5K | 0.00 | 0 |
| 2025-04-21 | HUMPHREY RACHEL Director | Open-market sale 10b5-1 plan | 13.9K | 1.03 | 14.3K |
| 2025-04-17 | HUMPHREY RACHEL Director | Open-market sale 10b5-1 plan | 200 | 0.97 | 194 |
| 2025-04-14 | HUMPHREY RACHEL Director | Open-market sale 10b5-1 plan | 1.4K | 0.97 | 1.4K |
| 2024-11-26 | Connealy Pamela Ann CFO & COO | Open-market purchase | 83.4K | 1.96 | 163.5K |
| 2024-11-26 | Connealy Pamela Ann CFO & COO | Open-market purchase | 5.5K | 2.00 | 10.9K |
| 2024-06-07 | Palani Santhosh Director | Grant or award | 6.0K | 0.00 | 0 |
| 2024-03-26 | Cline Darren S Director | Grant or award | 35.2K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Pfizer Inc | 9.2M | 7.0M |
| Laurion Capital Management LP | 7.3M | 5.0M |
| GordonMD Global Investments LP | 6.0M | 4.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | 2.0M |
| Atle Fund Management AB | 1.6M | 197.0K |
| Palo Alto Investors LP | 1.5M | 1.0M |
| 683 Capital Management, LLC | 1.3M | 896.3K |
| RENAISSANCE TECHNOLOGIES LLC | 1.3M | 888.7K |
| BlackRock, Inc. | 1.2M | 788.8K |
| GEODE CAPITAL MANAGEMENT, LLC | 873.8K | 598.1K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 4 | 2026-08-20 | 2026-08-20 | on EDGAR ↗ |
| S-3 | 2026-08-20 | — | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-12 | on EDGAR ↗ |
| 10-Q | 2026-08-13 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-13 | 2026-08-13 | on EDGAR ↗ |
| 3 | 2026-07-10 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-07-10 | — | on EDGAR ↗ |
| 4 | 2026-07-02 | 2026-06-30 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Pyxis Oncology, Inc. (PYXS) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about PYXS
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →